Extended Data Fig. 6: Oncoprint for Patients Receiving MTT.
From: Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
Tumor mutational burden (TMB) and additional alterations in 29 patients who received MTT. Additional alterations are shown if they occurred in >1 case or were potentially targetable. (For the case with high TMB all potentially actionable variants are not shown).
